Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

NCT02762006 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma
Kidney Cancer

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

Moshe Ornstein